Top

Pipeline

Multiple leads in development across multiple indications.

Evofosfamide

  • ETB
  • Generation
  • Target
  • Indication
  • Differentiation
  • Lead Selection
  • IND
  • Phase I
  • Phase II

  • MT-3724
  • 1st-Generation Forced Internalization Novel MOA
  • CD20
  • B-Cell Malignancies
  • CD20 Internalization Novel MOA


  • 80

  • MT-4019
  • 2nd-Generation
    De-immunized
  • CD38
  • Multiple Myeloma
  • Active on CD38 low, CD55/CD59 high tumor cells


  • 42

  • MT-5111
  • 2nd-Generation
    De-immunized
  • HER2
  • Breast Cancer
  • Novel epitope/combinable with Kadcyla Novel MoA
    Active in Kadcyla-refractory cells


  • 37

  • MT-5050
  • PD-L1+ tumors
  • PD-L1
  • Melanoma
  • Novel MoA Antigen seeding


  • 25

  • MT-6868
  • 1st-Generation
  • CD45
  • SCT
  • Novel MOA


  • 25